Celgosivir, an α-glucosidase I inhibitor for the potential treatment of HCV infection

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 860-870

  Durantel, David ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,6,7,8-TETRAHYDROXY OCTAHYDRO INDOLIZINE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ASPARAGINE LINKED OLIGOSACCHARIDE; BALAPIRAVIR; BOCEPREVIR; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; ENVELOPE PROTEIN; HEPATITIS C VACCINE; LOPERAMIDE; MIGLUSTAT; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLYCOSYLATION; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDOLIZINES; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; PRODRUGS; RIBAVIRIN;

EID: 68649083959     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. 50488 6-O-Butanoylcastanospermine (MDL 28, 574) inhibits glycoprotein processing and the growth of HIVs. Bowlin TL, Tyms AS, Taylor DL, Sunkara PS, Liu PS, Kang MS AIDS 1991 5 6 693-698 • First report on the antiviral activity of celgosivir.
2. 77522 Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Gruters RA, Neefjes JJ, Tersmette M, De Goede REY, Tulp A, Huisman HG, Miedema F, Ploegh HL NATURE 1987 330 6143 74-77 • One of the first reports establishing the antiviral activity of castanopsermine.
3. 82724 Inhibition of HIV replication by amino-sugar derivatives. Fleet GWJ, Karpas A, Dwek RA, Fellows LE, Tyms AS, Petursson S, Namgoong SK, Ramsden NG, Smith PW, Son JC, Wilson F et al FEBS LETT 1988 237 1-2 128-132
4. 84379 Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis. Taylor DL, Fellows LE, Farrar GH, Nash RJ, Taylor Robinson D, Mobberley MA, Ryder TA, Jeffries DJ, Tyms AS ANTIVIR RES 1988 10 1-3 11-26
5. 99458 Processing of the glycoprotein of feline immunodeficiency virus: Effect of inhibitors of glycosylation. Stephens EB, Monck E, Reppas K, Butfiloski EJ J VIROL 1991 65 3 1114-1123
6. 126633 Inhibition of glycoprotein processing and HIV replication by castanospermine analogues. Sunkara PS, Kang MS, Bowlin TL, Liu PS, Tyms AS, Sjoerdsma A ANN NY ACAD SCI 1990 616 90-96
7. 165640 Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg BS, Dwek RA PrOC NAtL ACAD SCI USA 1994 91 6 2235-2239
8. 167119 Inhibition of α-glucosidase I of the glycoprotein- processing enzymes by 6-O-butanoyl castanospermine (MDL 28, 574) and its consequences in human immunodeficiency virus-infected T cells. Taylor DL, Kang MS, Brennan TM, Bridges CG, Sunkara PS, Tyms AS ANTIMICrOB AGRNtS CHEMOtHER 1994 38 8 1780-1787
9. 168094 A concise, enantioselective synthesis of castanospermine. Kim NS, Choi JR, Cha JK J ORG CHEM 1993 58 25 7096-7099
10. 168096 The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase. Pan YT, Ghidoni J, Elbein AD ARCH BIOCHEM BIOPHYS 1993 303 1 134-144
11. 182958 Antiviral activity and metabolism of the castanospermine derivative MDL 28, 574, in cells infected with herpes simples virus type 2. Ahmed SP, Nash RJ, Bridges CG, Taylor DL, Kang MS, Porter EA, Tyms AS BIOCHEM BIOPHYS RES COMMUN 1995 208 1 267-273
12. 183096 Drug development pipeline: MDL-28577A. Marion Merrell Dow Inc COMPANY COMMUNICATION 1995 August 16
13. 244057 Uptake and metabolism of BuCast: A glycoprotein processing inhibitor and a potential anti-HIV drug. Kang MS GLYCOBIOLOGY 1996 6 2 209-216
14. 244092 The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28, 574) in the murine zosteriform model of HSV-1 infection. Bridges CG, Ahmed SP, Kang MS, Nash RJ, Porter EA, Tyms AS GLYCOBIOLOGY 1995 5 2 249-253
15. 244103 The prevention of cell adhesion and the cell-to-cell spread of HIV-1 in vitro by the α-glucosidase 1 inhibitor, 6-O-butanoyl castanospermine (MDL 28574). Bridges CG, Brennan TM, Taylor DL, McPherson M, Tyms AS ANTIVIR RES 1994 25 2 169-175
16. 277317 Pharmacokinetics of the glucosidase inhibitor MDL 28, 574 (BuCast) and its active metabolite MDL 26, 190 (castanospermine) in rats and dogs. Chang J, Scott DO, Wilson DD, Broward SM, Ho JC, Zadjura L, Stuhler JD, Rose JQ PHARM RES 1995 12 9 Suppl Abs PPDM 8057
17. 277318 Castanospermine analogues: Their inhibition of glycoprotein processing α-glucosidases from porcine kidney and B16F10 cells. Kang MS, Liu PS, Bernotas RC, Harry BS, Sunkara PS GLYCOBIOLOGY 1995 5 1 147-152
18. 277321 Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O-butanoylcastanospermine (MDL 28 574) in combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Taylor DL, Brennen TM, Bridges CG, Kang MS, Tyms AS ANTIVIR CHEM CHEMOTHER 1995 6 3 143-152
19. 277323 Two and three-drug synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-O- butanoylcastanospermine (MDL 28574), in combination with inhibitors of the HIV reverse transcriptase and proteinase. Brennan TM, Taylor DL, Bridges CG, Kang MS, Tyms AS J CELL BIOCHEM SUPPL 1994 18 Pt B Abs J 501
20. 277324 Effect of a glucosidase 1 inhibition on herpes simplex virus HSV glycoprotein synthesis and virus growth in-vitro. Kang M, Ahmed P, Tyms S J CELL BIOCHEM SUPPL 1993 17 Part A 382
21. 277326 Specific inhibition of a glucosidase 1 of the glycoprotein processing enzymes in HIV infected cells by 6-O butanoylcastanospermine MDL-28574. Taylor D, Brennan T, Kang M, Bridges G, Sunkara P, Tyms S J CELL BIOCHEM SUPPL 1992 0 16 Pt E 88
22. 277328 Castanospermine vs its 6-O-butanoyl analog: A comparison of toxicity and antiviral activity in vitro and in vivo. Ruprecht RM, Bernard LD, Bronson R, Gama Sosa MA, Mullaney S J ACQUIR IMMUNE DEFIC SYNDR (Pre-1999) 1991 4 1 48-55
23. 339449 Drug development pipeline: HMR-2420, HMR-4902, MDL-101002, MDL-101146, MDL-201449A, MDL-28170, MDL-28574, MDL-43291, ramorelix, rilopirox, trimegestone, cefotiam, lacidipine, reviparin sodium, ketolides, Aventis Pharma. Hoechst Marion Roussel AG COMPANY COMMUNICAtION 1999 September 10
24. 415859 Current and future treatment of hepatitis C. Manns MP, Cornberg M, Wedemeyer H INDIAN J GASTROENTEROL 2001 20 Suppl 1 C47-C51
25. 480489 Targeting glycosylation as a therapeutic approach. Dwek RA, Butters TD, Platt FM, Zitzmann N NAT REV DRUG DISCOV 2002 1 1 65-75 •• Comprehensive overview of the possible therapeutic options for targeting the glycosylation pathway.
26. 508663 Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents. Zitzmann N, Mehta AS, Carrouee S, Butters TD, Platt FM, McCauley J, Blumberg BS, Dwek RA, Block TM PROC NATL ACAD SCI USA 1999 92 21 11878-11882 • First study describing the antiviral properties of glucosidase inhibitors against the members of the Flaviviridae family.
27. 511549 PEGinterferon α-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago G, Carosi D, Dhumeaux D, Craxi A et al N ENGL J MED 2002 347 13 975-982
28. 520943 Micrologix acquires clinical-stage hepatitis C drug candidate. Micrologix Biotech Inc PRESS RELEASE February 03
29. 550016 Action of celgosivir against the pestivirus BVDV: Implications for the treatment of hepatitis C. Whitby K, Taylor D, Patel D, Ahmed P, Tyms AS ANTIVIR CHEM CHEMOTHER 2004 15 3 141-151
30. 564276 MIGENIX initiates hepatitis C phase II clinical study. MIGENIX Inc PRESS RELEASE 2004 October 13
31. 592841 Synergistic inhibition of flaviridae virus by celgosivir in combination with ribavirin or interferon-α. Dugourd D, Siu R, Fenn J, Clement JJ, Coulson R ANTIVIR RES 2005 65 3 Abs 101 • Describes the synergistic effect of IFN and celgosivir in vitro; the data provided a rationale for studying combination therapy in vivo.
32. 592842 Pharmacokinetics of celgosivir (MX-3253), a novel α-glucosidase-1 inhibitor, in loperamide-treated and diarrhoea-induced rats. Erfle D, Rubinchik E, Pasetka C, Friedland HD, Clement JJ ANTIVIR RES 2005 65 3 Abs 103
33. 592843 In vitro characterization of celgosivir, a clinical stage compound for the treatment of hepatitis C viral infections. Dugourd D, Fenn J, Siu R, Clement JJ, Coulson R ANTIVIR RES 2005 65 3 Abs 105
34. 612250 Schering-Plough to provide Pegetron for MIGENIX's HCV trial. MIGENIX Inc PRESS RELEASE 2005 July 13
35. 620457 Anti-HIV activity of castanospermine analogs. Sunkara PS, Taylor DL, Kang MS, Bowlin TL, Liu PS, Tyms AS LANCET 1989 1 8648 1206
36. 625327 MIGENIX completes first clinical study of celgosivir in chronic hepatitis C patients. MIGENIX Inc PRESS RELEASE 2005 September 27
37. 639210 Challenges and successes in developing new therapies for hepatitis C. De Francesco R, Migliaccio G NATURE 2005 436 7053 953-960
38. 668371 Results of a phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype-1 patients. Enns R, Yoshida E, Kunimoto D, Lee SS, Sherman M, Heathcote J GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs S1059
39. 668645 Celgosivir and castanospermine are highly synergistic against bovine viral diarrhea virus when combined with interferon α 2b or with interferon α 2b and ribavirin. Dugourd D, Siu RW, Fenn JR GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T1797
40. 668647 Pharmacokinetics of celgosivir, a novel antiviral agent, following oral administration in rats: Determination of the gastrointestinal first-pass effect. Rubinchik E, Erfie DJ, Clement JJ, Pasetka CJ GASTROENTEROLOGY 2006 130 4 Suppl 2 Abs T1799
41. 673701 Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS SCIENCE 1998 282 5386 103-107
42. 720525 Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD et al ANTIMICROB AGENTS CHEMOTHER 2006 49 10 4305-4314
43. 720550 Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R et al NAT MED 2005 11 7 791-796
44. 739414 MIGENIX's celgosivir combination therapy effective in HCV non-responders. MIGENIX Inc PRESS RELEASE 2006 November 06
45. 752382 Human Genome Sciences initiates phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive patients with chronic hepatitis C. Human Genome Sciences Inc PRERSS RELEASE 2006 December 19
46. 761329 Glucosidase inhibitors as antiviral agents for hepatitis B and C. Durantel D, Alotte C, Zoulim F CURR OPIN INVEST DRUGS 2007 8 2 125-129 • Summarizes the antiviral effects of glucosidase inhibitors.
47. 763625 MIGENIX provides update on license-option agreement with Schering-Plough for celgosivir in hepatitis C. MIGENIX Inc PRESS RELEASE 2007 February 06
48. 782482 New clinical study results indicate higher early virologic response with celgosivir combination therapy in HCV non-responders. MIGENIX Inc PRESS RELEASE 2007 April 11
49. 794557 Results of a phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Roberts S, Cooksley G, Dore G, Robson R, Shaw D, Berns H, Brandl M, Fettner S, Hill G, Ipe D, Klumpp K et al HEPATOLOGY 2006 44 4 Suppl Abs LB2
50. 795521 Phase II study of celgosivir in combination with PEGinterferon-α2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients. Kaita KD, Yoshida E, Kunimoto D, Anderson F, Sherman M, Marotta P, Scully LJ, Peltekian L, Enns RA, Diaz-Mitoma F, Lee SS et al DIGESTIVE DISEASE WEEKLY 2007 May 21 Abs 442 • Data from a phase IIb clinical trial of celgosivir in combination with PEGylated IFNα2b plus ribavirin; results report on the viral load reduction, early viral response and safety of the triple combination in partial or non-responders to PEGylated IFNα2b plus ribavirin therapy.
51. 804885 SCH 503034, a novel hepatitis C virus pro-tease inhibitor, plus PEGylated interferon α-2b for genotype 1 nonresponders. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S GASTROENTEROLOGY 2007 132 4 1270-1278
52. 809091 Schering declines option to license MIGENIX's celgosivir for HCV. MIGENIX Inc PRESS RELEASE 2007 June 27
53. 811706 Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C et al GASTROENTEROLOGY 2007 132 5 1767-1777
54. 812899 Valopicitabine development program placed on clinical hold in the United States. Idenix Pharmaceuticals Inc PRESS RELEASE 2007 July 13
55. 837456 Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, Bartenschlager R HEPATOLOGY 2007 46 2 330-338
56. 846934 Roche's investigational polymerase inhibitor, combined with PEGASYS and COPEGUS, shows potent antiviral activity in treatment of chronic hepatitis C at four weeks. Roche PRESS RELEASE 2007 November 02
57. 856690 MIGENIX reports preliminary celgosivir viral kinetics study. MIGENIX Inc PRESS RELEASE 2007 December 03
58. 857651 Efficacy and safety of valopicitabine in combination with pegylated interferon-α (PEGIFN) and ribavirin (RBV) in patients with chronic hepatitis C. Poordad F, Lawitz EJ, Gitlin N, Rodriguez-Torres M, Box T, Nguyen T, Pietropaolo K, Liu W, Fielman BA, Mayers D HEPATOLOGY 2007 46 4 Suppl 866A-866A
59. 894306 Antiviral activity of the α-glucosidase inhibitors celgosivir and castanospermine combined with NM-107, amantadine, and NB-DNJ. Dugourd D, Siu R, Clement J, Fenn J ANTIVIR RES 2006 70 1 Abs 120
60. 894307 Celgosivir and castanospermine are highly synergistic against bovine viral diarrhea virus when combined with interferon α 2b or with interferon a 2b and ribavirin. Dugourd D, Siu R, Fenn J ANTIVIR RES 2006 70 1 Abs 118
61. 894308 A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. Schul W, Liu W, Xu HY, Flamand M, Vasudevan Subhash G J INFECT DIS 2007 195 5 665-674
62. 894311 PhII proof of concept study of celgosivir in combination with PEGinterferon-α2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients. Kaita K, Yoshida E, Kunimoto D, Anderson F, Morris S, Marotta P, Scully L, Peltekian K, Enns R, Diaz-Mitoma F, Lee S et al J HEPATOL 2007 46 Suppl 1 Abs 127 • Results of a phase IIb clinical trial of celgosivir in combination with PEGylated IFNα2b plus ribavirin; the triple combination was well tolerated and more potent compared with celgosivir plus PEGylated IFNα2b and PEGylated IFNα2b plus ribavirin.
63. 910252 Migenix takes operational actions to extend cash past upcoming key milestones. MIGENIX Inc PRESS RELEASE 2008 May 27
64. 936225 R-1626 plus PEGinterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Najera I et al HEPATOLOGY 2008 48 2 385-397
65. 956209 Roche posts sustained double-digit sales growth for the first nine months of 2008. Roche Holding AG PRESS RELEASE 2008 October 27
66. 956754 Cytheris initiates asian phase I/IIa clinical trial of interleukin-7 (IL-7) as an immunotherapy in HCV patients. Cytheris SA PRESS RELEASE 2008 October 28
67. 967176 GI-5005 immunotherapy plus PEG-IFN/ribavirin in genotype 1 chronic hepatitis C patients compared to PEG-IFN/ribavirin alone in naive and non-responder patients; preliminary RVR and viral kinetic analysis from the GI-5005-02 phase 2 study. McHutchison JG, Lawitz EJ, Vierling JM, Everson GT, Jacobson IM, Shiffman ML, Boyer TD, Schiff ER, Cruickshank S, Rodell TC, Apelian D HEPATOLOGY 2008 48 4 S1 Abs LB9
68. 971398 Boceprevir plus PEGinterferon-α2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients: Interim results from the HCV SPRINT-1 study. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, Davis M, Galati J, Gordon S, Ravendhran N, Rossaro L et al ANN MEET AM ASSOC STUDY LIVRE DIS 2008 November 01 Abs LB16
69. 977571 Taribavirin exposure analysis from a previous phase 3 trial correlates with phase 2B weight based dosing interim results. Pockros P, Jacobson IM, Bacon BR, Afdhal NH, Poordad F, Chun E, Hammond J HEPATOLOGY 2008 48 4 Suppl 1138A-1139A
70. 1002730 Final results of boceprevir phase II HCV SPRINT-1 study showed significantly higher SVR rates compared to standard of care in treatment-naive genotype 1 hepatitis C patients. Schering-Plough Corp PRESS RELEASE 2009 April 23
71. 1002918 Biolex Therapeutics researchers present Locteron US phase 2a hepatitis C trial results at EASL conference. Biolex Therapeutics PRESS RELEASE 2009 April 24
72. 1003071 Roche and Pharmasset initiate phase IIb clinical trial of R7128, most advanced nucleoside polymerase inhibitor in development for chronic hepatitis C. Pharmasset Inc; Roche Holding AG PRESS RELEASE 2009 April 24
73. 1003840 Natural history of chronic hepatitis C. Seeff LB HEPATOLOGY 2002 36 5 Suppl 1 S35-S46
74. 1004053 Viral hepatitis and liver cancer: The case of hepatitis C. Levrero M ONCOGENE 2006 25 27 3834-3847
75. 1004056 Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Liang TJ, Heller T GASTROENTEROLOGY 2004 127 5 Suppl 1 S62-S71
76. 1004058 PEGinterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S et al ANN INTERN MED 2004 140 5 346-355
77. 1004066 The way forward in HCV treatment - Finding the right path. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M NAT REV DRUG DISCOV 2007 6 2 991-1000 • Reviews the current and future management of HCV infection.
78. 1004390 Total syntheses of (+)-castanospermine and (+)-deoxynojirimycin. Bernotas R, Ganem B TETRAHEDRON LETT 1984 25 2 165-168
79. 1004392 Total synthesis of (+)-castanospermine from d-mannose. Setoi H, Takeno H, Hashimoto M TETRAHEDRON LETT 1985 26 38 4617-4620
80. 1004394 A facile selective acylation of castanospermine. Anderson WK, Coburn RA, Gopalsamy A, Howe TJ TETRAHEDRON LETT 1990 31 2 169-170
81. 1004399 Synthesis of potent anti-HIV agents: Esters of castanospermine. Liu P, Hoekstra W, Kinga C TETRAHEDRON LETT 1990 31 20 2829-2832
82. 1004429 Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins. Saito T, Yamaguchi I J VET MED SCI 2000 62 6 575-581
83. 1004435 The effects of inhibitors of glucosidase I on the formation of Sindbis virus. Schlesinger S, Koyama AH, Malfer C, Gee SL, Schlesinger MJ VIRUS RES 1985 2 2 139-149
84. 1004438 Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing. Sunkara PS, Bowlin TL, Liu PS, Sjoerdsma A BIOCHEM BIOPHYS RES COMMUN 1987 147 1 206-210
85. 1004442 Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW, Diamond MS J VIROL 2005 79 14 8698-8706
86. 1004443 Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. Durantel D, Branza-Nichita N, Carrouee-Durantel S, Butters TD, Dwek RA, Zitzmann N J VIROL 2001 75 19 8987-8998
87. 1004447 α-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P J VIROL 2000 74 1 564-572
88. 1004452 Castanospermine and other plant alkaloid inhibitors of glucosidase activity block the growth of HIV. Tyms AS, Berrie EM, Ryder TA, Nash RJ, Hegarty MP, Taylor DL, Mobberley MA, Davis JM, Bell EA, Jeffries DJ LANCRT 1987 2 8566 1025-1026
89. 1004455 Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Walker BD, Kowalski M, Goh WC, Kozarsky K, Krieger M, Rosen C, Rohrschneider L, Haseltine WA, Sodroski J PROC NATL ACAD SCI USA 1987 84 22 8120-8124
90. 1004461 Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. Chapel C, Garcia C, Bartosch B, Roingeard P, Zitzmann N, Cosset FL, Dubuisson J, Dwek RA, Trepo C, Zoulim F, Durantel D J GEN VIROL 2007 88 Pt 4 1133-1143 • Explains, for the first time, how glucosidase inhibitors impair HCV infectivity in addition to decreasing virus morphogenesis.
91. 1004463 Castanospermine inhibits α-glucosidase activities and alters glycogen distribution in animals. Saul R, Ghidoni JJ, Molyneux RJ, Elbein AD PROC NATL ACAD SCI USA 1985 82 1 93-97
92. 1004465 Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Andersson U, Reinkensmeier G, Butters TD, Dwek RA, Platt FM BIOCHEM PHARMACOL 2004 67 4 697-705
93. 1004472 Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection. McGovern BH, Abu Dayyeh BK, Chung RT HEPATOLOGY 2008 48 5 1700-1712
94. 1004474 The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM, Chevaliez S, McHutchison JG GASTROENTEROLOGY 2007 132 5 1979-1998
95. 1004480 Antiretroviral resistance. Geretti AM J HIV THER 2006 11 4 72-73
96. 1004481 Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C HEPATOLOGY 2007 46 1 254-265
97. 1004487 Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A ANTIVIR RES 2007 73 1 78-83
98. 1004488 In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB et al J BIOL CHEM 2005 280 44 36784-36791
99. 1004828 Telaprevir with PEGinterferon and ribavirin for chronic HCV genotype 1 infection. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ N ENGL J MED 2009 360 18 1827-1838
100. 1004842 Telaprevir and PEGinterferon with or without ribavirin for chronic HCV infection. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L et al N ENGL J MED 2009 360 18 1839-1850
101. 1006461 Update on the clinical development of filibuvir, a non-nucleoside inhibitor of HCV polymerase. Hammon J INT CONF ANTIVIRAL RES 2009 22 May 05
102. 1011381 Pharmacokinetics of castanospermine in asymptomatic HIV-positive patients treated with MDL 28, 574A during phase I trials. Stoltz ML, McPherson M, Frampton M, Sidarous E, Jacobs M, Roth H INT AIDS CONF 1996 11 Abs Mo. B.1329.
103. 1011383 Phase I tolerance and pharmacokinetics of a new castanospermine derivative, MDL 28, 574A. Roth H, McPherson M, Hamedani P, Herrmann WM, Sidarous E, Frampton M, Maddern J, Dieterich A INT AIDS CONF 1996 11 Abs Tu. B.2117.
104. 1011384 Efficacy and safety of MDL 28, 574A in HIV-positive patients with baseline CD4 values of 301-500. Richmond GJ, Zolnouni P, Stall J, McPherson M, Hamedani P, Cross V, Sidarous E, Stoltz M INT AIDS CONF 1996 11 Abs Mo. B.1145.
105. 1011385 Efficacy and safety of MDL 28, 574A in HIV-positive patients with baseline CD4 values of 100-300. Zolmouni P, Berger DS, Perez G, Hamedani P, Frampton M, Gibson C, Sidarous E, Stoltz M INT AIDS CONF 1996 11 Abs Mo. B.1138.
106. 1011386 A randomized, double-blind, dose-ranging phase II European study of the safety and efficacy of chronically administered butanoyl-castanospermine (MDL 28, 574A) HIV-infected patients. Arasteh K, Czerwinska R, Schlote F, Fätkenheuer G, Jessen H, Moll A, Gehring P, Ulmer A, Hamedani P, McPherson M INT AIDS CONF 1996 11 Abs Mo. B.1121
107. 1012088 Investigation of the synergistic interactions of the α-glucosidase I inhibitor celgosivir with various interferons. Dugourd D, Fenn J, Cameron DR, Siu R, Clement J INT MEET HEPATITIS C VIRUS and RELAT VIRUSES 2006 13 Abs
108. 1012091 Celgosivir (MX-3253) resistance profile using bovine viral diarrhea virus. Dugourd D, Fenn J, Rojas F, Cameron DR, Clement JJ INT MEET HEPATITIS C VIRUS and RELAT VIRUSES 2007 14 Abs P-223
109. 1017548 Chapter 3: The burden of disease and mortality by condition: Data, methods and results for 2001. Mathers CD, Lopez AD, Murray CJL GLOBAL BURDEN DIS RISK FACTORS (EDS: LOPEZ AD, MATHERS CD, EZZATI M, JAMISON DT, MURRAY CJL) 2006 Oxford University Press, New York, NY, USA 45-240
110. 1020696 Studies on the mechanism of castanospermine inhibition of α-and β-glucosidases. Saul R, Molyneux RJ, Elbein AD ARCH BIOCHEM BIOPHYS 1984 230 2 668-675
111. 1021374 Development of novel treatments for hepatitis C. Webster DP, Klenerman P, Collier J, Jeffery KJ LANCET INFECT DIS 2009 9 2 108-117
112. 1021403 α-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C DIABETES CARE 2005 28 1 154-163
113. 1021496 Glycosylation of hepatitis C virus envelope proteins. Goffard A, Dubuisson J BIOCHIMIE 2003 85 3-4 295-301